Transforming growth factor beta 1 (TGF-β1) is the prototypic member of a large family of structurally related pleiotropic-secretedcytokines. The TGF-β1/SMAD signaling pathway usually participates in a wide range of cellular processes such as growth, proliferation, differentiation and apoptosis. Upon binding onTGF-β1, the dimerized TGF-β type II receptors recruit and phosphorylate the TGF-β type I receptors, which phosphorylate the receptor-regulated SMAD (SMAD2 and SMAD3) presented by the SMAD anchor for receptor activation.
The phosphorylated receptor-regulated SMAD form heterologous complexes with the common-mediator SMAD (SMAD4) and subsequently translocate into the nucleus, where they interact with other transcription factors to regulate the expression of target genes. This multi-functional signaling pathway modulated by various elements with complex mechanisms at different levels is also inevitably involved in cancer. We herein present data on the role of the TGF-β1/SMAD signaling pathway in human chronic myeloid leukemia and explain the potent biological effects of TGF-β1 on leukemia cells. The paper is based on a review of articles selected from Cancerline and Medline data bases.
The constitutively active tyrosine kinase produced by the specific Bcr-Abl fusion gene on the Philadelphia chromosome can enhance the resistance of malignant cells to TGF-β1-induced growth inhibition and apoptosis, which contributes to enhancement of proteasomal degradation of p27. However, overexpression of the EVI1 gene, which is also caused by Bcr-Abl, can recruit the C-terminal binding protein and histone deacetylase to prevent the MH2 domain on SMAD3. The later is essential for transcription activation on target genes and leads to blockage of the TGF-β1/SMAD signaling pathway.
Some studies have indicated that certain therapeutic agents applied in clinical treatment can inhibit proliferation and promote differentiation of leukemia cells by way of modulation of the TGF-β1/SMAD signal pathway. For example, arsenic trioxide can promote specific degradation of the AML1/MDS1/EVI1 oncoprotein and inhibit the proliferation of leukemia cells. However, specific histone deacetylase inhibitors can interrupt the effect of histone deacetylase to alleviate EVI1-mediated suppression of TGF-β1/SMAD signaling. The tyrosine kinase inhibitor in the target therapy of chronic myeloid leukemia can effectively inhibit the tyrosine kinase activity of Bcr-Abl and induce suppression on the TGF-β1/SMAD signaling pathway.
The TGF-β1/SMAD signaling pathway plays an important role in chronic myeloid leukemia cells and leads the leukemia cells to growth inhibition, differentiation and apoptosis. The positive influence of the TGF-β1/SMAD signaling pathway in chronic myeloid leukemia is fairly significant, and its potential effects in clinical treatment will bring about definite benefits.
Since it is a complex signaling pathway widely involved in many aspects of cellular activities, further study and comprehensive analysis of the TGF-β1/SMAD signaling pathway are imperative and will have a guiding significance in research and clinical applications. It is an exciting area for future research. Free full text available at www.tumorionline.it
MassaguéJ.: TGFß signal transduction. Annu Rev Biochem, 67: 753–791, 1998.
2.
SylvianceD., Marie-JoseG., Peter TenD.: Transforming growth factor ß signal transduction. J Leukocyte Biol, 71: 731–740, 2002.
3.
ShipleyG.D., PittelkowM.R., WilleJ.J., ScottR.E., MosesH.L.: Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res, 46: 2068–2071, 1986.
4.
RobertsA.B.: Molecular and cell biology of TGFβ. Miner Electrolyte Metab, 24: 111–119, 1998.
5.
LetterioJ.J., RobertsA.B.: Regulation of immune responses by TGFβ. Annu Rev Immunol, 16: 137–161, 1998.
6.
CerwenkaA., SwainS.L.: TGFβ1: Immunosuppressant and viability factor for T lymphocytes. Microbes Infect, 1: 1291–1296, 1999.
7.
LebmanD.A., EdmistonJ.S.: The role of TGFβ in growth, differentiation, and maturation of B lymphocytes. Microbes Infect, 1: 1297–1304, 1999.
8.
BlobeG.C., SchiemannW.P., LodishH.F.: Role of transforming growth factor ß in human disease. N Engl J Med, 342: 1350–1358, 2000.
9.
ItohS., ItohF., GoumansM-J, ten DijkeP.: Signaling of transforming growth factor ß family members through Smad proteins. Eur J Biochem, 267: 6954–6967, 2000.
10.
MassaguéJ., WottonD.: Transcriptional control by the TGFβ/Smad signaling system. EMBO J, 19: 1745–1754, 2000.
NowellP.C.: Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest, 117: 2033–2035, 2007.
15.
SavageD.G., SzydloR.M., GoldmanJ.M.: Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol, 96: 111–116, 1997.
16.
WranaJ.L., AttisanoL., CárcamoJ., ZentellaA., DoodyJ., LaihoM., WangX.F., MassaguéJ.: TGF beta signals through a heteromeric protein kinase receptor complex. Cell, 71: 1003–1014, 1992.
17.
FengX.H., DerynckR.: A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. EMBO J, 16: 3912–3923, 1997.
18.
AttisanoL., WranaJ.L.: Signal transduction by the TGF-beta superfamily. Science, 296: 1646–1647, 2002.
19.
WuJ.W., HuM., ChaiJ., SeoaneJ., HuseM., LiC., RigottiD.J., KyinS., MuirT.W., FairmanR., MassaguéJ., ShiY.: Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol Cell, 8: 1277–1289, 2001.
ShiY., HataA., LoR.S., MassaguéJ., PavletichN.P.: A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature, 388: 87–93, 1997.
22.
RunyanC.E., SchnaperH.W., PonceletA.C.: The role of internalization in transforming growth factor beta 1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells. J Biol Chem, 280: 8300–8308, 2005.
LapingN.J., GrygielkoE., MathurA., ButterS., BombergerJ., TweedC., MartinW., FornwaldJ., LehrR., HarlingJ., GasterL., CallahanJ.F., OlsonB.A.: Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol, 62: 58–64, 2002.
28.
BlobeG.C., LiuX., FangS.J., HowT., LodishH.F.: A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem, 276: 39608–39617, 2001.
29.
YouH.J., BruinsmaM.W., HowT., OstranderJ.H., BlobeG.C.: The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis, 28: 2491–2500, 2007.
ItohF., AsaoH., SugamuraK., HeldinC.H., ten DijkeP., ItohS.: Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J, 20: 4132–4142, 2001.
32.
LinX., LiangM., FengX.H.: Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem, 275: 36818–36822, 2000.
33.
FukasawaH., YamamotoT., TogawaA., OhashiN., FujigakiY., OdaT., UchidaC., KitagawaK., HattoriT., SuzukiS., KitagawaM., HishidaA.: Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA, 101: 8687–8692, 2004.
34.
FukuchiM., ImamuraT., ChibaT., EbisawaT., KawabataM., TanakaK., MiyazonoK.: Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol Biol Cell, 12: 1431–1443, 2001.
35.
PessahM., PrunierC., MaraisJ., FerrandN., MazarsA., LallemandF., GauthierJ.M., AtfiA.: c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity. Proc Natl Acad Sci USA, 98: 6198–6203, 2001.
36.
PessahM., MaraisJ., PrunierC., FerrandN., LallemandF., MauvielA., AtfiA.: c-Jun associates with the oncoprotein Ski and suppresses Smad2 transcriptional activity. J Biol Chem, 277: 29094–29100, 2002.
WahlS., HuntD., WongH., DoughertyS., McCartney-FrancisN., WahlL., EllingsworthL., SchmidtJ., HallG., RobertsA.: Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol, 140: 3026–3032, 1988.
41.
TiemessenM., KunzmannS., Schmidt-WeberC., GarssenJ., Bruijnzeel-KoomenC., KnolE., van HoffenE.: Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response. Int Immunol, 15: 1495–1504, 2003.
42.
RosendahlA., SpeletasM., LeanderssonK., IvarsF., SiderasP.: Transforming growth factor-beta- and activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis. Int Immunol, 15: 1401–1414, 2003.
43.
LebmanD., EdmistonJ.: The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect, 1: 1297–1304, 1999.
44.
MaroneM., ScambiaG., BonannoG., RutellaS., de RitisD., GuidiF., LeoneG., PierelliL.: Transforming growth factor-beta1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects. Leukemia, 16: 94–105, 2002.
45.
AkelS., BertoletteD., Petrow-SadowskiC., RuscettiF.W.: Levels of Smad7 regulate Smad and mitogen-activated kinases (MAPKs) signaling and controls erythroid and megakaryocytic differentiation of erythroleukemia cells. Platelets, 18: 566–578, 2007.
46.
RicardoM., TrzaskaK.A., RameshwarP.: Neurokinin-A inhibits cell cycle activators in K562 cells and activates Smad4 through a non-canonical pathway: a novel method in neural-hematopoietic axis. J Neuroimmunol, 204: 85–91, 2008.
47.
HuX., MoscinskiL.C., ZuckermanK.S.: Transforming growth factor beta inhibits growth of more differentiated myeloid leukemia cells and retinoblastoma protein phosphorylation at serine 795. Exp Hematol, 27: 605–614, 1999.
48.
JimiS., MashimaK., MatsumotoT., HaraS., SuzumiyaJ., TamuraK.: RARalpha is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells. Int J Oncol, 31: 397–404, 2007.
49.
AkhlyninaT.V., GerasimovaL.P., SarkisianG.P., BorovkovaT.V., DukhovenskaiaE.A., ManakovaT.E., NaïdenovaN.M., TimofeevA.M., GrinevaN.I.: Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells. Tsitologiia, 49: 889–900, 2007.
JonuleitT., van der KuipH., MiethingC., MichelsH., HallekM., DuysterJ., AulitzkyW.E.: Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood, 96: 1933–1939, 2000.
52.
WarmuthM., Danhauser-RiedlS., HallekM.: Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol, 78: 49–64, 1999.
53.
MøllerG.M., FrostV., MeloJ.V., ChantryA.: Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. FEBS Lett, 581: 1329–1334, 2007.
54.
CuencoG.M., RenR.: Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene, 20: 8236–8248, 2001.
55.
KurokawaM., MitaniK., ImaiY., OgawaS., YazakiY., HiraiH.: The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood, 92: 4003–4012, 1998.
56.
YatsulaB., LinS., ReadA.J., PoholekA., YatesK., YueD., HuiP., PerkinsA.S.: Identification of binding sites of EVI1 in mammalian cells. J Biol Chem, 280: 30712–30722, 2005.
57.
BuonamiciS., ChakrabortyS., SenyukV., NuciforaG.: The role of EVI1 in normal and leukemic cells. Blood Cells Mol Dis, 31: 206–212, 2003.
58.
SatoT., GoyamaS., NittaE., TakeshitaM., YoshimiM., NakagawaM., KawazuM., IchikawaM., KurokawaM.: Evi-1 promotes para-aortic splanchnopleural hematopoiesis through up-regulation of GATA-2 and repression of TGF-β signaling. Cancer Sci, 99: 1407–1413, 2008.
59.
LiuY., ChenL., KoT.C., FieldsA.P., ThompsonE.A.: EVI1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene, 25: 3565–3575, 2006.
60.
AllistonT., KoT.C., CaoY., LiangY.Y., FengX.H., ChangC., DerynckR.: Repression of bone morphogenetic protein and activin-inducible transcription by EVI-1. J Biol Chem, 280: 24227–24237, 2005.
61.
IzutsuK., KurokawaM., ImaiY., MakiK., MitaniK., HiraiH.: The corepressor CtBP interacts with EVI-1 to repress transforming growth factor signaling. Blood, 97: 2815–2822, 2001.
62.
MitaniK.: Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene, 23: 4263–4269, 2004.
63.
NittaE., IzutsuK., YamaguchiY., ImaiY., OgawaS., ChibaS., KurokawaM., HiraiH.: Oligomerization of EVI-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. Oncogene, 24: 6165–6173, 2005.
64.
HiraiH., IzutsuK., KurokawaM., MitaniK.: Oncogenic mechanisms of EVI-1 protein. Cancer Chemother Pharmacol, 48 Suppl 1: S35–40, 2001.
65.
SenyukV., ChakrabortyS., MikhailF.M., ZhaoR., ChiY., NuciforaG.: The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene, 21: 3232–3240, 2002.
66.
ShackelfordD., KenificC., BlusztajnA., WaxmanS., RenR.: Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res, 66: 11360–11369, 2006.
67.
HamiltonA., AlhashimiF., MyssinaS., JorgensenH.G., HolyoakeT.L.: Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Exp Hematol, 37: 395–401, 2009.
68.
DeremerD.L., UstunC., NatarajanK.: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther, 30: 1956–1975, 2008.
69.
Gora-TyborJ., RobakT.: Targeted drugs in chronic myeloid leukemia. Curr Med Chem, 15: 3036–3051, 2008.
